These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 15705133)

  • 1. Has the time come to prescribe azithromycin in cystic fibrosis patients?
    McCormack JG; Bell SC
    Intern Med J; 2005 Feb; 35(2):73-4. PubMed ID: 15705133
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of azithromycin in patients with cystic fibrosis.
    Yousef AA; Jaffe A
    Paediatr Respir Rev; 2010 Jun; 11(2):108-14. PubMed ID: 20416547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macrolide resistance of Staphylococcus aureus and Haemophilus species associated with long-term azithromycin use in cystic fibrosis.
    Phaff SJ; Tiddens HA; Verbrugh HA; Ott A
    J Antimicrob Chemother; 2006 Apr; 57(4):741-6. PubMed ID: 16469851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring the mechanisms of macrolides in cystic fibrosis.
    Equi AC; Davies JC; Painter H; Hyde S; Bush A; Geddes DM; Alton EW
    Respir Med; 2006 Apr; 100(4):687-97. PubMed ID: 16185859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapidly progressive lung disease in a patient with cystic fibrosis on long-term azithromycin: possible role of mycoplasma infection.
    Janahi IA; Abdulwahab A; Elshafie Sittana S; Bush A
    J Cyst Fibros; 2005 Mar; 4(1):71-3. PubMed ID: 15752685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Azithromycin for cystic fibrosis.
    Southern KW; Barker PM
    Eur Respir J; 2004 Nov; 24(5):834-8. PubMed ID: 15516680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Macrolides, Pseudomonas aeruginosa and cystic fibrosis].
    Guillot M; Amiour M; El Hachem C; Harchaoui S; Ribault V; Paris C
    Arch Pediatr; 2006 Oct; 13 Suppl 1():S48-50. PubMed ID: 17370396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term azithromycin may improve lung function in children with cystic fibrosis.
    Jaffé A; Francis J; Rosenthal M; Bush A
    Lancet; 1998 Feb; 351(9100):420. PubMed ID: 9482305
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacokinetics of azithromycin in plasma, blood, polymorphonuclear neutrophils and sputum during long-term therapy in patients with cystic fibrosis.
    Wilms EB; Touw DJ; Heijerman HG
    Ther Drug Monit; 2006 Apr; 28(2):219-25. PubMed ID: 16628134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoantibodies against bactericidal/permeability-increasing protein (BPI-ANCA) in cystic fibrosis patients treated with azithromycin.
    Rotschild M; Elias N; Berkowitz D; Pollak S; Shinawi M; Beck R; Bentur L
    Clin Exp Med; 2005 Jul; 5(2):80-5. PubMed ID: 16096858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term, low-dose azithromycin treatment reduces the incidence but increases macrolide resistance in Staphylococcus aureus in Danish CF patients.
    Hansen CR; Pressler T; Hoiby N; Johansen HK
    J Cyst Fibros; 2009 Jan; 8(1):58-62. PubMed ID: 18849202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of clinical trials in cystic fibrosis.
    Southern KW; Smyth RL
    Lancet; 2003 Jan; 361(9354):349-50; aurhor reply 350. PubMed ID: 12559892
    [No Abstract]   [Full Text] [Related]  

  • 13. Molecular characterization of macrolide resistance determinants [erm(B) and mef(A)] in Streptococcus pneumoniae and viridans group streptococci (VGS) isolated from adult patients with cystic fibrosis (CF).
    Tazumi A; Maeda Y; Goldsmith CE; Coulter WA; Mason C; Millar BC; McCalmont M; Rendall J; Elborn JS; Matsuda M; Moore JE
    J Antimicrob Chemother; 2009 Sep; 64(3):501-6. PubMed ID: 19584106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How long should we maintain long-term azithromycin treatment in cystic fibrosis patients?
    Willekens J; Eyns H; Malfroot A
    Pediatr Pulmonol; 2015 Jan; 50(1):103-4. PubMed ID: 24464958
    [No Abstract]   [Full Text] [Related]  

  • 15. Azithromycin, the multidrug-resistant protein, and cystic fibrosis.
    Altschuler EL
    Lancet; 1998 Apr; 351(9111):1286. PubMed ID: 9643772
    [No Abstract]   [Full Text] [Related]  

  • 16. Azithromycin in cystic fibrosis.
    Kastelik JA; Peckham DG; Conway S
    Eur Respir J; 2005 Apr; 25(4):771; author reply 771-2. PubMed ID: 15802355
    [No Abstract]   [Full Text] [Related]  

  • 17. Do cystic fibrosis patients on azithromycin need electrocardiogram monitoring?
    Sharpton R; Condren M; O'Neal K; Lloyd A; McIntosh H
    Pulm Pharmacol Ther; 2017 Apr; 43():55-56. PubMed ID: 28219728
    [No Abstract]   [Full Text] [Related]  

  • 18. Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function.
    Tramper-Stranders GA; Wolfs TF; Fleer A; Kimpen JL; van der Ent CK
    Pediatr Infect Dis J; 2007 Jan; 26(1):8-12. PubMed ID: 17195698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study.
    Hansen CR; Pressler T; Koch C; Høiby N
    J Cyst Fibros; 2005 Mar; 4(1):35-40. PubMed ID: 15752679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Approaches to the synthesis of immunolides: selective immunomodulatory macrolides for cystic fibrosis.
    Fecik RA; Nguyen PL; Venkatraman L
    Curr Opin Drug Discov Devel; 2005 Nov; 8(6):741-7. PubMed ID: 16312149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.